Literature DB >> 18201065

Rationalizing the activities of diverse cholecystokinin 2 receptor antagonists using molecular field points.

Caroline M R Low1, J G Vinter.   

Abstract

Cholecystokinin 2 receptor antagonists encompass a wide range of structures. This makes them unsuitable candidates for existing 3D-QSAR methods and has led us to develop an alternative approach to account for their observed biological activities. A diverse set of 21 antagonists was subjected to a novel molecular field-based similarity analysis. The hypothesis is that compounds with similar field patterns will bind at the same target site regardless of their underlying structure. This initial report demonstrates a linear correlation between ligand similarity and biological activity for this challenging data set. A model generated with three molecules was used to predict the activity of 18 test compounds, with different chemotypes, with a root-mean-square error of 0.68 pKB units. The ability to automatically derive a molecular alignment without knowledge of the protein structure represents an improvement over existing pharmacophore methods and makes the method particularly suitable for scaffold-hopping.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18201065     DOI: 10.1021/jm070880t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  QSAR modeling: where have you been? Where are you going to?

Authors:  Artem Cherkasov; Eugene N Muratov; Denis Fourches; Alexandre Varnek; Igor I Baskin; Mark Cronin; John Dearden; Paola Gramatica; Yvonne C Martin; Roberto Todeschini; Viviana Consonni; Victor E Kuz'min; Richard Cramer; Romualdo Benigni; Chihae Yang; James Rathman; Lothar Terfloth; Johann Gasteiger; Ann Richard; Alexander Tropsha
Journal:  J Med Chem       Date:  2014-01-06       Impact factor: 7.446

Review 2.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

Review 3.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

4.  Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement.

Authors:  Marina Tuyishime; Matt Danish; Amy Princiotto; Marie K Mankowski; Rae Lawrence; Henry-Georges Lombart; Kirill Esikov; Joel Berniac; Kuang Liang; Jingjing Ji; Roger G Ptak; Navid Madani; Simon Cocklin
Journal:  Bioorg Med Chem Lett       Date:  2014-12-01       Impact factor: 2.823

Review 5.  Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn
Journal:  Int Immunopharmacol       Date:  2015-09-15       Impact factor: 4.932

6.  Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.

Authors:  Liliya N Kirpotina; Andrei I Khlebnikov; Igor A Schepetkin; Richard D Ye; Marie-Josèphe Rabiet; Mark A Jutila; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2009-11-10       Impact factor: 4.436

7.  Core chemotype diversification in the HIV-1 entry inhibitor class using field-based bioisosteric replacement.

Authors:  Marina Tuyishime; Rae Lawrence; Simon Cocklin
Journal:  Bioorg Med Chem Lett       Date:  2015-10-27       Impact factor: 2.823

8.  Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors.

Authors:  Heba Alshaker; Shyam Srivats; Danielle Monteil; Qi Wang; Caroline M R Low; Dmitri Pchejetski
Journal:  Breast Cancer Res Treat       Date:  2018-07-24       Impact factor: 4.872

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.